Skip to Content

Division of Pediatrics - Division Priority List

MD Anderson

Pediatric Clinical Trials

  

Disease Type Phase / Type Title Physician Contact / Phone Protocol Number
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Acute Lymphoblastic Leukemia (ALL)
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Acute Myelogenous Leukemia (AML)
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Acute Myelogenous Leukemia (AML) / Myelodysplastic Syndrome (MDS)
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Aplastic Anemia
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Brainstem Glioma/ Pontine Glioma
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Central Nervous System (CNS)
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Central Nervous System/Brain Tumors
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Chronic Lymphocytic Leukemia
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Chronic Myeloid Leukemia (CML)
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Ependymoma
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Hodgkin's Disease
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Laboratory
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Medulloblastoma/Primitive Neuroectodermal Tumors (PNET)/Embryonal Tumors
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Non-Hodgkin's Lymphoma
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Other
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Other, Blood/BM Collection
cell therapy (bone marrow transplantation) - Pediatric Tumors/Conditions  Pediatric Tumors/Conditions
   II PBMTC ONC-032; High dose Temozolomide, Thiotepa, and Carboplatin with Autologous Stem Cell Rescue (ASCR) followed by continuous therapy with 13-cis-retinoic acid in patients with recurrent/refractory malignant brain tumors Worth, Laura L., M.D., Ph.D. askMDAnderson
(713) 795-2058
2007-0028